Dr Reddy’s Zytorvi Approval: DCGI Clears Cancer Drug for Esophageal Cancer, October 21, 2026

Dr Reddy’s Zytorvi approval for a second cancer indication came through on Wednesday, October 21, 2026. India’s drug regulator has cleared the company’s immunotherapy drug Zytorvi (toripalimab) as a first-line treatment for advanced esophageal squamous cell carcinoma (ESCC), according to a press release Dr Reddy’s filed with NSE on Wednesday morning. The stock barely reacted.

What the Dr Reddy’s Zytorvi approval covers

The Central Drugs Standard Control Organisation, which works under the Drugs Controller General of India (DCGI), approved Zytorvi in combination with two chemotherapy drugs, cisplatin and paclitaxel. It is for adults whose ESCC is unresectable, advanced, recurrent or metastatic. In plain terms, these are patients where surgery is no longer the answer. The reference list in the filing shows the CDSCO approval letter is dated September 24, 2026, so the public announcement came about four weeks after the letter.

One detail matters for how widely the drug can be used. Doctors don’t need to test patients for PD-L1 expression before prescribing it for this indication. The company says that mirrors the European approval, which also covers first-line ESCC irrespective of PD-L1 levels. The European Commission authorised toripalimab for that use in September 2024.

The trial data behind it

The approval rests on the Phase 3 JUPITER-06 trial. As per the filing, toripalimab plus paclitaxel and cisplatin cut the risk of disease progression or death by 42% compared with chemotherapy alone. At the final overall-survival analysis, median survival was 17.7 months on the combination against 12.9 months on chemotherapy alone, a gap of 4.8 months.

The disease burden is large. Citing 2024 data, Dr Reddy’s says esophageal cancer was the fourth leading cause of cancer deaths in India, accounting for about 8.1% of them, and that ESCC makes up roughly 80% of esophageal cancer cases in the country.

How Zytorvi fits into Dr Reddy’s portfolio

This is not a home-grown molecule. Dr Reddy’s signed a licensing and commercialisation deal with Shanghai Junshi Biosciences in 2023, which gives it exclusive rights to toripalimab in 21 countries, including India, South Africa and Brazil. It launched Zytorvi in India in November 2024 for recurrent or metastatic nasopharyngeal carcinoma. The Hindu notes that this made India only the third country, after China and the US, to get access to the drug.

Toripalimab is a PD-1 antibody. It blocks a signal that tumours use to switch off the immune system’s T-cells. The drug is also approved by the US FDA, the European Medicines Agency and the UK’s MHRA. M.V. Ramana, who heads Global Generics at Dr Reddy’s, described the second indication as a step in widening access to immunotherapy and said oncology remains a focus area.

Stock reaction on October 21

CNBC-TV18 reported that the shares were down 0.38%, or ₹4.70, at ₹1,237.80 at the time of its 1:39 pm update. The same report said the stock has fallen nearly 4% over the past year.

The approval was not the only Dr Reddy’s headline that day. CNBC-TV18’s pharma round-up also said the US FDA issued a Form 483 with two observations after an assessment at the company’s API manufacturing unit in Mexico. So traders had an inspection outcome to weigh alongside the oncology news.

What it means

We’d read this as a steady portfolio-building move rather than a near-term earnings trigger. The filing gives no pricing or sales estimate for the new indication, so any revenue impact is guesswork for now. What it does show is Dr Reddy’s leaning into in-licensed oncology for the Indian market, a space where Sun Pharma has also been active, as we covered in our post on Sun Pharma’s Unloxcyt. For investors tracking the sector, regulatory news like this is worth weighing alongside plant inspection outcomes, and our guide to a sector rotation strategy explains how pharma fits into a wider allocation view.

Disclaimer: This article is for information and education only and is not investment advice. Please do your own research or speak to a SEBI-registered adviser before making investment decisions.